New drug combo tested to shrink tumors before stomach cancer surgery
NCT ID NCT04661150
Summary
This study is testing whether adding a new immunotherapy drug (atezolizumab) to a standard chemotherapy and targeted therapy combination works better before surgery for people with a specific type of stomach or gastroesophageal cancer (HER2-positive). The goal is to shrink the tumor as much as possible to improve the chance of successful surgery and long-term control of the cancer. It involves 42 participants who have not yet had treatment for their cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, 100142, China
-
First Hospital of China Medical University
Shenyang, 110001, China
-
Harbin Medical University Cancer Hospital
Harbin, 150081, China
-
Liaoning Provincial Cancer Hospital
Shengyang, 110042, China
-
Nanfang Hospital, Southern Medical University
Guangzhou, 510515, China
-
Tianjin Medical University Cancer Institute & Hospital
Tianjing, 300060, China
-
West China Hospital, Sichuan University
Chengdu, 610041, China
-
Zhongshan Hospital Fudan University
Shanghai, 200032, China
Conditions
Explore the condition pages connected to this study.